Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
Fortress Biotech Inc FBIO
News
-
Avenue Therapeutics Announces Reverse Stock Split
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
Fortress Biotech to Participate in 36th Annual ROTH Conference
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market